(50%) in this combined depression cohort received an SSRI. Women with depression had increased alcohol and tobacco use, BMI and premature delivery rates (p < 0.01). Maternal depression was associated with an increased frequency of neonatal intensive care unit (NICU) admission (p < 0.001). In addition to depression, maternal SSRI use, obesity and smoking were univariate predictors of NICU admission. Conclusions: Among women with depression, the use of an SSRI was not associated with significant differences in any of the measured maternal or neonatal parameters, but further studies are needed to evaluate the specific effects of SSRI exposure in early or late gestation. Despite SSRI utilization, women with depression continue to have increased risks during pregnancy.
Introduction
Depression is common during pregnancy, with an estimated prevalence of 7-13% [1] [2] [3] . Approximately 7% of pregnant women receive an antidepressant, most frequently selective serotonin reuptake inhibitors (SSRIs) [3, 4] . The management of maternal depression during pregnancy is accompanied by difficult decisions regarding the risks and benefits of medication therapy for both mother and baby.
Untreated depression during pregnancy has been associated with increased risks of alcohol and tobacco use, miscarriage, preterm birth, low birth weight and impaired fetal and postnatal development [1, [5] [6] [7] . While there are clear risks associated with untreated depression, there have been mixed results from studies looking at the effect of SSRIs on fetal outcomes. Some studies report increased risks of cardiovascular malformations [8] [9] [10] [11] [12] , craniosynostosis [13] and omphalocele [10, 13] upon exposure to any SSRI in early pregnancy. Other studies show an increased risk of preterm delivery [2, [14] [15] [16] , low-birthweight and small-for-gestational age infants [2, 16] , neonatal abstinence syndrome [2, [17] [18] [19] [20] and persistent pulmonary hypertension of the newborn [21] . Conversely, some studies have failed to replicate these findings [22, 23] .
Given the prevalence of depression and SSRI utilization in pregnancy, it is important to improve our current knowledge regarding the risks of depression and its treatment for maternal and fetal outcomes. Thus, we sought to compare the perinatal outcomes of women carrying a diagnosis of depression during pregnancy who either received an SSRI or did not.
Materials and Methods

Study Population
This study was approved by the University of Iowa Institutional Review Board, and informed consent was waived. Linked maternal-neonatal records of women who delivered at the University of Iowa Hospitals and Clinics (UIHC) from April 1, 2009 to March 2, 2011 were obtained. The records were screened for the diagnosis of depression by separating them based on the presence or absence of the following International Classification of Diseases (ICD)-9 codes: 311 (depressive disorder, not elsewhere classified), 296.2 (major depressive disorder, single episode), 296.3 (major depressive disorder, recurrent episode), 300.4 (anxious depression) and 309.0 (adjustment disorder with depression). An equal number of women (n = 238) who gave birth during the same time period who did not have any of these ICD-9 codes for depression were randomly selected by hospital record number as potential controls.
Maternal Medical Record Review
Prenatal clinic notes, psychiatry clinic notes and hospital admission notes were reviewed for the duration of the pregnancy. The use of antidepressants during pregnancy was identified based on medication record and medical chart review. The maternal medical records were reviewed for the diagnosis of depression and completion of the Patient Health Questionnaire (PHQ-9), a 9-item questionnaire widely used to screen for depression [24] . The PHQ-9 is used in the obstetrical clinic at UIHC to screen pregnant women at the initial clinic visit. Each item on the PHQ-9 is rated on a 4-point Likert scale, with a score of 5-10 suggesting mild depression, 11-16 suggesting moderate depression and >16 suggesting severe depression. If multiple PHQ-9 forms were completed by a pregnant woman, the initial score was recorded. Maternal age at delivery, BMI at onset of pregnancy and weight gain during pregnancy were recorded. Alcohol and tobacco use were defined as consumption between the time of conception and delivery as noted in the patient's medical chart. No information was collected on nonpharmacologic therapies to treat depression.
Neonatal Medical Record Evaluation
The admission notes, progress notes and discharge notes of infants born to the selected mothers were reviewed during the delivery encounter. Gestational age and birth weight were recorded. Repeated measurements of heart rate, blood pressure and respiratory rate during the initial 24 h after birth were recorded. Birth weight percentiles were calculated based on data from 6,690,717 births in the 1999-2000 US Natality Datasets [5] . Admission to the neonatal intensive care unit (NICU) and admission diagnosis were obtained when applicable. Values in parentheses represent percentages. 1 PHQ-9 scores were available for 133 patients without depression and 174 patients with depression.
Statistical Analysis
Data are presented as means ± SEM. Statistical comparisons were made with Student's two-tailed t test or χ 2 analysis, as appropriate. χ 2 tests and bivariate logistic regression were used to determine factors associated with NICU admission. A binary logistic regression model was created to assess the effect of depression and SSRI use on NICU admission, adjusting for significant covariates within the entire study population. All variables included in the final models were chosen based on previously known associations for modifying or confounding maternal depression outcomes and/ or a bivariate association with the outcome variable with a p value <0.2. Statistical analysis was performed using SAS (SAS Institute Inc., Cary, N.C., USA) and SPSS (SPSS, Chicago, Ill., USA). A twosided 0.05-level test was considered significant.
Results
Maternal Characteristics
Of the 3,695 women who delivered during the study period, 238 (6.4%) had an ICD-9 code for depression, with the majority of these (94%) carrying the ICD-9 code 311 for depressive disorder, not elsewhere classified. Of the 3,457 women who did not have an ICD-9 code for depression, 238 randomly selected charts were reviewed. Sixteen of these women (6.7%) had depression listed in their medical records but did not have an ICD-9 code for depression. Their data were removed from the nondepressed group and combined with those of the 238 women carrying an ICD-9 code for depression for subsequent analysis. Table 1 compares the demographic characteristics of women with and without a diagnosis of depression. The PHQ-9 was completed by 65% of women in the sample, with women with depression rating significantly higher, albeit in the mild range. Depression was strongly associated with the use of alcohol and tobacco during pregnancy as well as obesity at conception.
Of the 254 women with depression, 126 (50%) were prescribed an SSRI and 23 (9%) were prescribed an antidepressant other than SSRIs. In addition, 2 women received an SSRI plus bupropion, and 1 woman received sertraline plus bupropion and nortriptyline ( table 2 ) . SSRI therapy was not associated with PHQ-9 scores ( table 3 ). Likewise, the 105 depressed women who received no pharmacotherapy for depression did not differ significantly in terms of PHQ-9 scores from those who received any antidepressant (no treatment 7.24 ± 0.5, pharmacotherapy 7.06 ± 0.5; p = 0.83). Compared to women with depression who did not receive an SSRI, those who did receive an SSRI did not differ in the frequency of alcohol and tobacco use or obesity ( table 3 ) . Some women received more than 1 medication. 
Neonatal Characteristics
The mean duration of gestation was more than 1 week shorter and the rate of prematurity was higher in infants born to mothers with depression compared to mothers without depression ( table 1 ) . When corrected for gestational age at delivery, birth weight was not significantly altered by maternal depression. The frequency of NICU admission nearly doubled for infants born to mothers with depression, and this was driven by an increase in admission for respiratory distress ( table 1 ) . Looking specifically at pregnancies in mothers with depression, SSRI use did not significantly alter the timing of delivery, birth weight or the rate of NICU admission ( table 3 ) . Using logistic regression to analyze univariate predictors of NICU admission, maternal depression, maternal SSRI use, obesity and tobacco use were all associated with NICU admission (p < 0.05; table 4 ). With the multivariate model, tobacco use, obesity and diagnosis of depression, but not SSRI use, were independently associated with NICU admission ( table 5 ) .
Discussion
Due to the high prevalence of antenatal depression and common use of SSRIs to treat depression, it is important to understand their effects on perinatal outcomes. Using linked maternal-fetal records for births at the UIHC over an approximate 2-year time period, we were able to compare outcomes between SSRI-treated depression, depression without SSRI therapy and a control population without depression. Women with depression had higher rates of substance use, preterm delivery and subsequent neonatal intensive care admission, and these deleterious outcomes did not appear to be affected by the prescription of SSRI treatment. A strength of this case-control study is that we accounted for several confounding variables which can affect both depression as well as neonatal outcomes. Between these two groups, maternal depression was associated with alcohol use, tobacco use and obesity. Another strength of our study was that women with depression on SSRI therapy and not on SSRI therapy had similar disease severity, potentially limiting bias when measuring neonatal outcomes. Mean PHQ-9 scores for all depressed women indicated mild severity of disease, regardless of treatment with an SSRI (7.4), alternative antidepressants (5.0) or no antidepressants (7.2). However, this could reflect a medication-induced improvement in symptoms among those receiving pharmacotherapy.
In our study, neonates born to depressed mothers had an increased risk of NICU admission, and this was unaffected by the presence of maternal SSRI prescription. To help control for confounding variables, logistic regression was used to assess the effect of depression and SSRI use on NICU admission. When a multivariate model was used, tobacco use, obesity and depression were associated with NICU admissions. SSRI use, when adjusted for other variables, was not associated with an increase or decrease in NICU admissions. In our study, a significant percentage of infants were admitted to the NICU, even in the control group (23%). UIHC is a tertiary care center and is the primary referral center in the state of Iowa, which may contribute to the high number of NICU admissions. In addition, there are no continuous monitoring capabilities in our newborn nursery, necessitating NICU admission for infants with mild distress. The majority of admissions were for respiratory distress. Overall, 13.1% of our maternal population had either an ICD-9 diagnosis of depression or self-reported depression, consistent with national prevalence rates of maternal depression [1] [2] [3] .
Few studies have been completed comparing neonatal outcomes of unmedicated and medicated depressed mothers. A recent review summarizes these studies [6] . Suri et al. [7] found no significant differences in birth weight, gestational age or intensive care admissions for depressed mothers treated prenatally with fluoxetine [7] , suggesting that women with mild to moderate depression were included. Although our study also included mildly depressed women at the time of information intake, alcohol use, tobacco use and obesity were assessed and were significantly higher in the depressed population. Oberlander et al. [2] found in a large population-based linked health data study that neonates exposed to depression had shorter gestations, lower birth weights and longer hospital stays than control neonates. When comparing the depressed groups, they found that neonates of the medicated depressed mothers had a shorter gestation period and longer hospital stays compared to those of unmedicated depressed mothers [2] . El Marroun et al. [25] also found increased incidence of alcohol and tobacco use in depressed mothers, but they found the SSRI-treated group twice as likely to have preterm births.
Beyond the implications of depression on the mother and child, the high prevalence of maternal obesity in our population-based cohort warrants mention. Studies have increasingly shown that maternal BMI correlates with birth weight and the subsequent risk of metabolic syndrome in the offspring [26] . Perhaps this underlies the trend towards increased birth weight percentile seen in our depressed population, despite the presence of risk factors for decreased birth weight, including alcohol and tobacco use during pregnancy. This comorbid maternal obesity may have contributed to the adverse pregnancy outcomes experienced by those with depression, including the higher incidence of NICU admission.
Several limitations do exist in this study. Firstly, we do not know if the women on SSRI therapy were compliant. No drug levels were measured and we did not assess prescription filling information. In addition, we do not know if the women on SSRIs took the medication during the third trimester, which is considered a susceptible period for neonatal adaptation syndrome [27, 28] , or tapered the medication throughout pregnancy. It was not possible to determine whether the ICD-9 codes for depression were entered by psychiatrists, psychologists or other health care professionals. We do not know the severity of depression in patients on medical therapy prior to initiation of treatment or when treatment was initiated in relation to time of conception. In our depressed group, approximately 10% of women were not on an SSRI but were on another type of antidepressant, which may have influenced outcomes. To exclude potential bias, a sensitivity analysis was performed comparing pharmacologically treated depressed women versus nontreated depressed women which did not significantly change our findings. We did not assess the use of any nonpsychopharmacologic treatments. All of these factors could have influenced maternal and fetal outcomes. In addition, our sample size was limited, but the effect size we found in our study does not suggest a larger study would likely identify a clinically relevant independent effect of maternal SSRI therapy on NICU admission rates.
Among women with depression, the use of an SSRI was not associated with significant differences in any of the measured maternal or neonatal parameters, but further studies are needed to evaluate the specific effects of SSRI exposure in early or late gestation. Evaluating neonatal outcomes in the context of maternal depression continues to be challenging. Multiple variables likely contribute to the puzzle, including maternal health, adverse effects of depression, potential adverse effects from pharmacotherapy and environmental factors including social support, financial resources and substance use. The literature continues to be sparse when evaluating psychotropic effects on neonates. Clearly, prenatal interventions are needed to lessen the impact of illicit substance use, obesity and psychiatric illness.
